Abstract
The treatment of bifurcation lesions (BLs) is associated with high procedural complication and restenosis rates. Two techniques of BL interventions were compared: the simultaneous kissing stents (SKS) technique, involving 2 stents, 1 in the main vessel and 1 in the side branch (n = 100), and the conventional stent strategy (CSS) technique, involving a stent in the main vessel and provisional stenting for the side branch (n = 100). In-hospital and 30-day major adverse cardiac events were greater in the CSS group, with significantly less procedure time with the SKS technique. The incidence of target lesion revascularization was 5% in the SKS group and 18% in the CSS group (p = 0.007). Therefore, the SKS technique seems to be rapid, safe, and effective for the treatment of medium- to large-size BLs, with a trend toward fewer acute complications and promising mid-term results.
Publication types
-
Comparative Study
-
Evaluation Study
MeSH terms
-
Abciximab
-
Aged
-
Angioplasty, Balloon, Coronary / methods
-
Antibodies, Monoclonal / therapeutic use
-
Biomarkers / blood
-
Blood Vessel Prosthesis Implantation / methods*
-
Clopidogrel
-
Coated Materials, Biocompatible / therapeutic use
-
Combined Modality Therapy
-
Coronary Angiography
-
Coronary Stenosis / diagnostic imaging
-
Coronary Stenosis / therapy*
-
Coronary Vessels / pathology
-
Coronary Vessels / surgery
-
Creatine Kinase / blood
-
Creatine Kinase, MB Form
-
Disease-Free Survival
-
Equipment Design / instrumentation
-
Female
-
Follow-Up Studies
-
Humans
-
Immunoglobulin Fab Fragments / therapeutic use
-
Isoenzymes / blood
-
Male
-
Middle Aged
-
Multivariate Analysis
-
Myocardial Infarction / blood
-
Myocardial Infarction / etiology
-
New York
-
Platelet Aggregation Inhibitors / therapeutic use
-
Postoperative Complications / blood
-
Postoperative Complications / etiology
-
Severity of Illness Index
-
Stents*
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / therapeutic use
-
Treatment Outcome
-
Troponin I / blood
Substances
-
Antibodies, Monoclonal
-
Biomarkers
-
Coated Materials, Biocompatible
-
Immunoglobulin Fab Fragments
-
Isoenzymes
-
Platelet Aggregation Inhibitors
-
Troponin I
-
Clopidogrel
-
Creatine Kinase
-
Creatine Kinase, MB Form
-
Ticlopidine
-
Abciximab